Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • FROM THE ANALYST'S COUCH
  • Correction 20 April 2023

Immuno-oncology clinical trials take a turn beyond PD1/PDL1 inhibitors

  1. Ana Rosa Saez-Ibanez

    1. Cancer Research Institute, New York City, NY, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Samik Upadhaya

    1. Cancer Research Institute, New York City, NY, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Jay Campbell

    1. Cancer Research Institute, New York City, NY, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

For more than a decade now, the global landscape of immuno-oncology (IO) clinical trials has been dominated by studies testing PD1 and PDL1 inhibitors, whether as monotherapy or in combinations. However, in 2022 that trend started to change. In this analysis, the Cancer Research Institute (CRI) provides its latest assessment on the global IO landscape, including year-by-year comparisons on therapy modalities, targets, and indications addressed in trials starting between 2018 and 2022.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 22, 442-443 (2023)

doi: https://doi.org/10.1038/d41573-023-00066-0

Updates & Corrections

  • Correction 20 April 2023: The bars showing the number of clinical trials in all therapeutic modalities in Figure 1b were flipped in the horizontal plane; however, the values given for each year were correctly assigned. The figure has been corrected.

Supplementary Information

  1. Supplementary Figures

Competing Interests

The authors declare no competing interests.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links